For most of the last century, psilocybin sat outside the reach of clinical research entirely. That changed over the past decade, as regulatory approvals reopened the door to controlled human trials.
What's emerged since is a growing, still-early body of clinical data on psilocybin as an investigational treatment for depression — particularly treatment-resistant depression, a form of the illness that doesn't respond to two or more standard antidepressants. This piece summarizes what that research says, how the compound is thought to work, and where the evidence remains incomplete.
For the roughly four million Americans whose depression resists two or more treatments, the standard cycle — try a drug, wait weeks, try the next — can stretch on for years.
How psilocybin is thought to act on the brain
Psilocybin is a prodrug — the body converts it into psilocin, which is the compound that's pharmacologically active. Psilocin's primary mechanism is agonism at the 5-HT2A serotonin receptor, a receptor densely expressed in the cortex and involved in regulating mood, perception, and cognition.
Researchers studying this mechanism point to a few downstream effects that may be relevant to depression specifically:
Neuroplasticity. Preclinical work suggests 5-HT2A activation can promote dendritic growth and synaptic remodeling — the kind of structural flexibility thought to be reduced in chronic depression.
Brain network connectivity. Neuroimaging studies report temporary disruption of the default mode network — a set of brain regions associated with self-referential thought and rumination — followed by altered connectivity patterns that some researchers associate with the sustained mood effects reported after dosing.
It's worth being precise about the state of this science: these are proposed mechanisms supported by imaging and preclinical data, not a fully settled account of how or why clinical effects occur.
What the clinical data shows
As of 2026, more than 60 studies are registered on ClinicalTrials.gov exploring psilocybin for various mental health conditions, with depression as the primary focus.
In an early open-label trial of psilocybin-assisted psychotherapy, 63% of 19 participants with treatment-resistant depression responded one week after treatment, and 32% remained off antidepressants and therapy a year later.
A 24-participant RCT for major depressive disorder reported large effect sizes compared with a waitlist control at both week 1 and week 4. A 12-month follow-up on the same cohort found response and remission rates of 75% and 58%, respectively.
The first Phase 3 data for a classic psychedelic in treatment-resistant depression showed a mean treatment difference of -3.8 points on the MADRS scale for the 25mg dose versus a 1mg comparator, with 39% of high-dose participants meeting the company's threshold for a clinically meaningful response — a lower bar than the 50% reduction typically used to define response in antidepressant trials.
A second pivotal trial testing two fixed doses also achieved its primary endpoint, with rapid onset of response maintained through week six in the 25mg arm.
Regulatory movement has followed the data: Compass Pathways' Phase 3 program has proceeded under an independent Data Safety Monitoring Board that has reported no unexpected safety findings to date, and the company has indicated plans to pursue formal drug approval. That process is ongoing and not yet complete — psilocybin is not an FDA-approved treatment for any condition as of this writing.
Quick reference
What the evidence doesn't yet show
Open questions in the current research
- Trial size and duration. Many foundational studies involved small cohorts (20–30 participants); durability of effects beyond 6–12 months is still being established in larger trials.
- Controlled settings matter. Every trial cited here paired dosing with structured psychological support before, during, and after administration — not self-directed use.
- Not yet an approved treatment. Phase 3 data is promising but regulatory review is ongoing; no psilocybin formulation is currently FDA-approved for any indication.
- Response definitions vary. Some trials use a lower bar for "response" (25% symptom reduction) than the traditional antidepressant standard (50%), which affects how headline results should be read.
- Legal status. Psilocybin remains federally controlled in the U.S. and in most countries; legal access outside of licensed research or the small number of regulated jurisdictions (e.g., Oregon and Colorado's supervised service models) is not sanctioned.
Carhart-Harris et al., open-label psilocybin pilot, Imperial College London · Davis et al., RCT and 12-month follow-up, Johns Hopkins · Compass Pathways, COMP005 and COMP006 Phase 3 topline results (2025–2026) · ClinicalTrials.gov registry data, 2026. Full citations available on request.
We follow the research, and we're honest about where it stands.
Omnyx Labs tracks emerging fungal and mycological science because the field moves fast and the claims often outrun the evidence. This piece exists to summarize the clinical picture accurately — not to sell, recommend, or facilitate access to a controlled substance.